Travere Therapeutics Appoints Bradley L. Campbell as CEO Following Eric Dube Resignation

Key Facts

In a move reflecting executive shifts within the biotechnology sector, Travere Therapeutics has announced a transition in its top leadership. According to reports, Eric Dube has resigned from his role as CEO to focus on health and family matters. The Board of Directors has appointed Bradley L. Campbell, the former CEO of Amicus Therapeutics, as his successor to lead the company forward.

This transition occurs as biotech firms prioritize management stability through proven industry leadership. Campbell brings extensive experience from his previous tenure at Amicus Therapeutics, which may help mitigate the uncertainty typically associated with executive changes. Per market data, the company remains under observation as leadership responsibilities shift to ensure the continuity of strategic operations.

Shares of TVTX stood at $62.76 at close on September 18, 2026, after reaching a day high of $64.89 and a low of $62.47. With no specific upcoming catalysts listed in the economic calendar for the immediate future, investors will be watching for market reactions as the new leadership officially assumes its duties.